PP
CRNX icon

PDT Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

PDT Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,031
Closed -$220K – 990
2022
Q1 		$220K Buy
+10,031
New +$203K 0.02% 797
2021
Q3 		– Sell
-11,410
Closed -$215K – 792
2021
Q2 		$215K Sell
11,410
-3,129
-22% -$55K 0.01% 688
2021
Q1 		$222K Sell
14,539
-12,260
-46% -$190K 0.02% 682
2020
Q4 		$378K Buy
26,799
+3,558
+15% +$49.6K 0.03% 503
2020
Q3 		$364K Buy
+23,241
New +$355K 0.02% 516

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PDT Partners's CRNX Position: Q2 2022 in Review

PDT Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2022, closing a stake of 10,031 shares — an estimated $220K sold.

PDT Partners first reported a position in CRNX in Q3 2020 and held it in 5 quarters. The position peaked at $378K in Q4 2020. 111 funds tracked by Wall St. Rank hold CRNX as of Q2 2022.

  • PDT Partners reported no remaining Crinetics Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 10,031 Crinetics Pharmaceuticals shares in Q2 2022, an estimated $220K.
  • PDT Partners first reported a position in Crinetics Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • PDT Partners's Crinetics Pharmaceuticals position peaked at $378K in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.